Rituximab-induced tumor progression: Does it really happen?

Medical Oncology

Volumn 21, Issue 2, 2004, Pages 205-206

  Ozguroglu, Mustafa ^a   Turna, Hande ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ALLERGIC REACTION; CHILL; FEVER; HUMAN; LETTER; LYMPHADENOPATHY; NONHODGKIN LYMPHOMA; PAIN; PRIORITY JOURNAL; SIDE EFFECT; TUMOR GROWTH; TUMOR LYSIS SYNDROME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FATAL OUTCOME; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE;

EID: 4243083095     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:21:2:205     Document Type: Letter

References (17)

1. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol 2002;29(1 Suppl 2):105-112.
2. Czuczman MS, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002;29(1 Suppl 2):36-40.
3. Al-Salman J, Salib H, Boonswang P. Successful treatment of gastrointestinal follicular lymphoma with rituxan and combination chemotherapy. Med Oncol 2001;18(4):277-283.
4. Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 2001;115(3):609-611.
5. Chemnitz J, Draube A, Diehl V, Wolf J. Successful treatment of steroid and cyclophosphamide-resistant hemolysis in chronic lymphocytic leukemia with rituximab. Am J Hematol 2002;69(3):232-233.
6. Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002;116(2):465-467.
7. Zaja F, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002;87(2):189-195.
8. Treon SP, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002;25(1):72-81.
9. Coiffier B, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl Med J Med 2002;346:235-242.
10. Coiffier B. Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol 2002;29(1 Suppl 2):30-35.
11. Korte W, Jost C, Cogliatti S, Hess U, Cerny T. Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy. Ann Oncol 1999;10(10):1249-1250.
12. Bellosillo B, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001;98(9):2771-2777.
13. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115(4):807-811.
14. Cardarelli PM, et al. Binding to CD20 by Anti-B1 Antibody or F(ab′)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002;51(1):15-24.
15. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29(1 Suppl 2):2-9.
16. Chow KU, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002;87(1):33-43.
17. Bienvenu J, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2001;2(6):378-384.